Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1583107 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $16.85Day +0.00%Mkt cap $869MP/E (FY) 8.2×1Y +52.2%Off 52W high −19.9%Vol (1Y) 46.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 3,067 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.4% of sh out |
| Days to cover5.3d |
| 13F net flow (QoQ)+2.13% |
| Top-10 13F concentration71.5% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)8.2× |
| Sales (TTM)$109.8M |
| Earnings (TTM)$114.5M |
| ROE44.8% |
| Net margin98.5% |
| ROIC−2.2% |
| EPS growth 3Y−44.2% |
| Sales growth 3Y27.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−9.9% |
| 1Y+52.2% |
| 3Y+70.4% |
| 5Y+29.8% |
| 10Y−36.2% |
| Since incept. (ann.)−2.5% |
Total return through 2026-07-30 · series begins 2014-05-16. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)46.4% |
| Ann. volatility (3Y)43.7% |
| Sharpe (1Y)1.16 |
| Sharpe (3Y)0.63 |
| Max drawdown (1Y)−34.6% |
| Max drawdown (3Y)−34.6% |
| Beta (3Y vs SPY)0.61 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Madison Avenue Partners, LP | 9.5M | $154M | 18.47% | +0.0% |
| Weiss Asset Management LP | 7.5M | $121M | 14.48% | +0.0% |
| Newtyn Management, LLC | 4.8M | $79M | 9.40% | +12.6% |
| BlackRock, Inc. | 4.3M | $70M | 8.34% | +6.1% |
| Irenic Capital Management LP | 2.8M | $45M | 5.36% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.8M | $29M | 3.46% | new |
| STATE STREET CORP | 1.3M | $21M | 2.52% | +17.7% |
| ACADIAN ASSET MANAGEMENT LLC | 1.3M | $21M | 2.48% | +9.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.10 | — | $17.7M | +15.0% |
| 2025-12-31 | 2026-03-19 | $1.15 | — | $45.9M | +144.7% |
| 2025-09-30 | 2025-11-10 | $0.07 | — | $20.0M | +18.5% |
| 2025-06-30 | 2025-08-12 | $1.08 | — | $26.2M | +83.7% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Single Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
